Trials / Completed
CompletedNCT03103724
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer patients with at least one visceral site involvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xtandi | Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily |
Timeline
- Start date
- 2017-03-16
- Primary completion
- 2021-04-23
- Completion
- 2021-04-23
- First posted
- 2017-04-06
- Last updated
- 2021-04-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03103724. Inclusion in this directory is not an endorsement.